GLP-1 Receptor Agonist Market Global Report 2026

The glp-1 receptor agonist market size has grown rapidly in recent years. It will grow from $65.87 billion in 2025 to $76.65 billion in 2026 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period can be attributed to the rising prevalence of type 2 diabetes, increased awareness of glycemic control therapies, strong clinical efficacy compared with traditional antidiabetics, physician preference for incretin-based therapies, and favorable reimbursement in developed markets.

The glp-1 receptor agonist market size is expected to see rapid growth in the next few years. It will grow to $139.27 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth during the forecast period can be attributed to the growing obesity population, expanding approvals for cardiovascular risk reduction, innovations in oral and combination therapies, increasing penetration in emerging markets, and rising patient preference for weight loss benefits. Key trends during the forecast period include expansion of GLP-1 therapies beyond diabetes, increasing demand for long-acting and once-weekly formulations, growing adoption of oral GLP-1 receptor agonists, greater focus on weight management indications, and strategic partnerships and licensing agreements.

The rising prevalence of diabetes is expected to propel the growth of the GLP-1 receptor agonist market going forward. Diabetes is a chronic condition that occurs when the pancreas does not produce sufficient insulin or when the body is unable to effectively use the insulin it produces. Elevated blood sugar levels are a key characteristic of diabetes mellitus. GLP-1 receptor agonists are used to manage diabetes by stimulating the body to produce more insulin, thereby helping reduce blood glucose levels, and the increasing prevalence of diabetes is therefore expected to support market growth. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while the corresponding percentage for type 2 diabetes increased by 21%, and the percentage achieving target HbA1c levels rose to 37.9%. Therefore, the rising prevalence of diabetes is driving the GLP-1 receptor agonist market.

Major companies operating in the GLP-1 receptor agonist market are focusing on developing sustained-release GLP-1 receptor agonists to strengthen their competitive position in the market. Sustained-release GLP-1 receptor agonists (GLP-1RAs) are medications designed to gradually release GLP-1RA into the bloodstream over an extended period, enabling longer-lasting effects and less frequent injections compared to conventional GLP-1RAs. For instance, in April 2023, Mitsubishi Tanabe Pharma Corporation, a Japan-based pharmaceuticals company, launched Mounjaro 2.5 mg or 5 mg Ateos. It is the world’s first sustained-release GIP/GLP-1 receptor agonist for the treatment of type 2 diabetes that activates both GLP-1 and GIP receptors. The GLP-1 receptor plays a role in regulating blood glucose levels, while the GIP receptor contributes to insulin secretion and appetite reduction.

In July 2024, Roche, a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics for US$2.7 billion, along with up to US$400 million in additional milestone payments. Through this acquisition, Roche aimed to strengthen its metabolic disease franchise by gaining access to Carmot’s advanced portfolio, particularly its phase-2-ready dual GLP-1/GIP receptor agonist, thereby enhancing its competitive position in the obesity and diabetes markets. Carmot Therapeutics is a US-based biotechnology company focused on developing incretin-based therapies, including CT-388, a weekly injectable dual GLP-1/GIP agonist; CT-996, an oral small-molecule GLP-1 agonist; and CT-868, another injectable GLP-1/GIP candidate.

Major companies operating in the glp-1 receptor agonist market are Novo Nordisk A/S, Sanofi SA, Eli Lilly and Company, AstraZeneca Inc., Boehringer Ingelheim International GmbH, Hanmi Pharm Co. Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics Inc., Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., PegBio Co. Ltd., Zealand Pharma A/S, Bristol-Myers Squibb Company, Chongqing Lummy Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Dong-A ST Co. Ltd., Eisai Co. Ltd., HanAll Biopharma Co. Ltd., Ipsen SA, Johnson & Johnson, Merck & Co. Inc., Novartis AG.

North America was the largest region in the GLP-1 receptor agonist market in 2025. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the glp-1 receptor agonist market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the glp-1 receptor agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.